{"id":"NCT00615030","sponsor":"Novartis","briefTitle":"Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A Phase III Randomized, Double Blind, Double Dummy, Placebo Controlled, Multicenter, 4 Treatments, 3 Period Incomplete Block Crossover Study to Assess the Efficacy and Safety of Indacaterol 300 µg o.d. Dosed in the Evening in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Salmeterol 50 µg b.i.d. as Active Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2008-07","completion":"2008-08","firstPosted":"2008-02-14","resultsPosted":"2011-08-17","lastUpdate":"2011-08-17"},"enrollment":96,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"Indacaterol","otherNames":["QAB149"]},{"type":"DRUG","name":"Salmeterol","otherNames":["Serevent®"]},{"type":"DRUG","name":"Placebo to Indacaterol","otherNames":[]},{"type":"DRUG","name":"Placebo to Salmeterol","otherNames":[]}],"arms":[{"label":"Indacaterol Morning,Indacaterol Evening, Salmeterol","type":"EXPERIMENTAL"},{"label":"Indacaterol Evening,Indacaterol Morning, Placebo","type":"EXPERIMENTAL"},{"label":"Salmeterol, Placebo, Indacaterol Morning","type":"EXPERIMENTAL"},{"label":"Placebo, Salmeterol, Indacaterol Evening","type":"EXPERIMENTAL"},{"label":"Indacaterol Morning, Placebo, Indacaterol Evening","type":"EXPERIMENTAL"},{"label":"Indacaterol Evening,Salmeterol, Indacaterol Morning","type":"EXPERIMENTAL"},{"label":"Salmeterol, Indacaterol Evening, Placebo","type":"EXPERIMENTAL"},{"label":"Placebo, Indacaterol Morning, Salmeterol","type":"EXPERIMENTAL"},{"label":"Indacaterol Morning, Salmeterol, Placebo","type":"EXPERIMENTAL"},{"label":"Indacaterol Evening, Placebo, Salmeterol","type":"EXPERIMENTAL"},{"label":"Salmeterol, Indacaterol Morning, Indacaterol Evening","type":"EXPERIMENTAL"},{"label":"Placebo, Indacaterol Evening, Indacaterol Morning","type":"EXPERIMENTAL"}],"summary":"This study was conducted to provide detailed information on the efficacy of indacaterol (in terms of the spirometry assessment forced expiratory volume in 1 second \\[FEV1\\]) over the full 24-h time period","primaryOutcome":{"measure":"Trough Forced Expiratory Volume in 1 Second (FEV1) Following 14 Days of Evening Dosing of Indacaterol Versus Placebo","timeFrame":"After 14 days of treatment","effectByArm":[{"arm":"Indacaterol Evening","deltaMin":1.57,"sd":0.025},{"arm":"Placebo","deltaMin":1.37,"sd":0.025}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":7,"countries":["France","Germany","Spain"]},"refs":{"pmids":["20850959"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":65},"commonTop":["Chronic obstructive pulmonary disease","Cough"]}}